[1] |
中华医学会皮肤性病学分会免疫学组, 特应性皮炎协作研究中心. 中国特应性皮炎诊疗指南(2020版)[J]. 中华皮肤科杂志, 2020,53(2):81⁃88. doi: 10.35541/cjd.20191000.
|
[2] |
Wollenberg A, Christen⁃Zäch S, Taieb A, et al. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children[J]. J Eur Acad Dermatol Venereol, 2020,34(12):2717⁃2744. doi: 10. 1111/jdv.16892.
|
[3] |
中华医学会皮肤性病学分会儿童皮肤病学组. 中国儿童特应性皮炎诊疗共识(2017版)[J]. 中华皮肤科杂志, 2017,50(11):784⁃789. doi: 10.3760/cma.j.issn.0412⁃4030.2017.11.002.
|
[4] |
Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis[J]. J Am Acad Dermatol, 2014,70(2):338⁃351. doi: 10.1016/j.jaad.2013.10.010.
|
[5] |
王建琴. 中国特应性皮炎诊疗指南(2020版)解读[J]. 皮肤性病诊疗学杂志, 2020,27(5):359⁃361. doi: 10.3969/j.issn.1674⁃8468.2020.05.016.
|
[6] |
王侠生, 张学军, 徐金华. 现代皮肤病学[M]. 2版. 上海: 上海大学出版社, 2020:554.
|
[7] |
Abuabara K, Margolis DJ, Langan SM. The long⁃term course of atopic dermatitis[J]. Dermatol Clin, 2017,35(3):291⁃297. doi: 10.1016/j.det.2017.02.003.
|
[8] |
Zuberbier T, Orlow SJ, Paller AS, et al. Patient perspectives on the management of atopic dermatitis[J]. J Allergy Clin Immunol, 2006,118(1):226⁃232. doi: 10.1016/j.jaci.2006.02.031.
|
[9] |
Smith S, Baker C, Gebauer K, et al. Atopic dermatitis in adults: An Australian management consensus[J]. Australas J Dermatol, 2020,61(1):23⁃32. doi: 10.1111/ajd.13124.
|
[10] |
Katoh N, Ohya Y, Ikeda M, et al. Japanese guidelines for atopic dermatitis 2020[J]. Allergol Int, 2020,69(3):356⁃369. doi: 10. 1016/j.alit.2020.02.006.
|
[11] |
Howells L, Thomas KS, Sears AV, et al. Defining and measuring ′eczema control′: an international qualitative study to explore the views of those living with and treating atopic eczema[J]. J Eur Acad Dermatol Venereol, 2019,33(6):1124⁃1132. doi: 10.1111/jdv.15475.
|
[12] |
Barbarot S, Rogers NK, Abuabara K, et al. Strategies used for measuring long⁃term control in atopic dermatitis trials: A systematic review[J]. J Am Acad Dermatol, 2016,75(5):1038⁃1044. doi: 10.1016/j.jaad.2016.05.043.
|
[13] |
Pariser DM, Simpson EL, Gadkari A, et al. Evaluating patient⁃perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT)[J]. Curr Med Res Opin, 2020,36(3):367⁃376. doi: 10.1080/03007995.2019.1699516.
|
[14] |
Beasley R, Braithwaite I, Semprini A, et al. Optimal asthma control: time for a new target[J]. Am J Respir Crit Care Med, 2020,201(12):1480⁃1487. doi: 10.1164/rccm.201910⁃1934CI.
|
[15] |
Langan SM, Silcocks P, Williams HC. What causes flares of eczema in children?[J]. Br J Dermatol, 2009,161(3):640⁃646. doi: 10.1111/j.1365⁃2133.2009.09320.x.
|
[16] |
Thomas KS, Koller K, Dean T, et al. A multicentre randomised controlled trial and economic evaluation of ion⁃exchange water softeners for the treatment of eczema in children: the Softened Water Eczema Trial (SWET)[J]. Health Technol Assess, 2011,15(8):v⁃vi, 1⁃156. doi: 10.3310/hta15080.
|
[17] |
Harrison EF, Haines RH, Cowdell F, et al. A multi⁃centre, parallel group superiority trial of silk therapeutic clothing compared to standard care for the management of eczema in children (CLOTHES Trial): study protocol for a randomised controlled trial[J]. Trials, 2015,16:390. doi: 10.1186/s13063⁃015⁃0921⁃9.
|
[18] |
Langan SM, Stuart B, Bradshaw L, et al. Measuring long⁃term disease control in patients with atopic dermatitis: a validation study of well⁃controlled weeks[J]. J Allergy Clin Immunol, 2017,140(6):1580⁃1586. doi: 10.1016/j.jaci.2017.02.043.
|
[19] |
Schmitt J, Spuls P, Boers M, et al. Towards global consensus on outcome measures for atopic eczema research: results of the HOME Ⅱ meeting[J]. Allergy, 2012,67(9):1111⁃1117. doi: 10.1111/j.1398⁃9995.2012.02874.x.
|
[20] |
Schmitt J, Williams H. Harmonising Outcome Measures for Eczema (HOME). Report from the First International Consensus Meeting (HOME 1), 24 July 2010, Munich, Germany[J]. Br J Dermatol, 2010,163(6):1166⁃1168. doi: 10.1111/j.1365⁃2133.2010.10054.x.
|
[21] |
Chalmers JR, Simpson E, Apfelbacher CJ, et al. Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative)[J]. Br J Dermatol, 2016,175(1):69⁃79. doi: 10.1111/bjd.14773.
|
[22] |
Chalmers JR, Schmitt J, Apfelbacher C, et al. Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME)[J]. Br J Dermatol, 2014,171(6):1318⁃1325. doi: 10.1111/bjd.13237.
|
[23] |
Chalmers JR, Thomas KS, Apfelbacher C, et al. Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative)[J]. Br J Dermatol, 2018,178(5):e332⁃e341. doi: 10.1111/bjd.16543.
|
[24] |
Thomas KS, Apfelbacher CA, Chalmers JR, et al. Recommended core outcome instruments for health⁃related quality of life, long⁃term control and itch intensity in atopic eczema trials: results of the HOME Ⅶ consensus meeting[J]. Br J Dermatol, 2021,185(1):139⁃146. doi: 10.1111/bjd.19751.
|
[25] |
Howells LM, Chalmers JR, Gran S, et al. Development and initial testing of a new instrument to measure the experience of eczema control in adults and children: Recap of atopic eczema (RECAP)[J]. Br J Dermatol, 2020,183(3):524⁃536. doi: 10.1111/bjd. 18780.
|
[26] |
Gerbens LA, Boyce AE, Wall D, et al. TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema registries[J]. Trials, 2017,18(1):87. doi: 10.1186/s13063⁃016⁃1765⁃7.
|
[27] |
Gerbens L, Apfelbacher CJ, Irvine AD, et al. TREatment of ATopic eczema (TREAT) Registry Taskforce: an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema photo⁃ and systemic therapy registries[J]. Br J Dermatol, 2019,180(4):790⁃801. doi: 10. 1111/bjd.16714.
|
[28] |
Vermeulen FM, Gerbens L, Bosma AL, et al. TREatment of ATopic eczema (TREAT) Registry Taskforce: consensus on how and when to measure the core dataset for atopic eczema treatment research registries[J]. Br J Dermatol, 2019,181(3):492⁃504. doi: 10.1111/bjd.17715.
|
[29] |
Simpson E, Eckert L, Gadkari A, et al. Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic⁃treated patients with atopic dermatitis[J]. BMC Dermatol, 2019,19(1):15. doi: 10.1186/s12895⁃019⁃0095⁃3.
|
[30] |
De Bruin⁃Weller M, Biedermann T, Bissonnette R, et al. Treat⁃to⁃target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies[J]. Acta Derm Venereol, 2021,101(2):adv00402. doi: 10.2340/00015555⁃3751.
|